CEO Update | 4 July 2022

It was great to spend this morning in Stevenage with the Chancellor of the Exchequer, Rishi Sunak MP, Jonathan Symonds and Tony Wood of GSK as UBS Asset Management and Reef Group announced up to £900 million investment in to developing land at the GSK site in Stevenage to create an estimated 1.4m sq. foot of laboratory space and 5,000 new highly skilled jobs.

UK biotech leaders urge policy makers to boost sector as economic climate worsens

The UK biotech sector has continued to attract investment despite global economic headwinds impacting all sectors, new data published by the UK BioIndustry Association (BIA) and Clarivate shows today (30 June 2022). The data has been published as biotech leaders visit the Houses of Parliament to press policy makers to make the most of the UK’s competitive advantage to be at the forefront of global innovation in the 21st Century. The new data on equity investment in the UK biotech and life sciences sector between March and May 2022 shows £450m was raised, compared to £481m in the first quarter of 2022

New HealthTech directorship at CPI to boost innovation that will urgently improve global health and care

We’re pleased to announce that we’ve appointed Rahul Kapoor as our first HealthTech Director, marking our purposeful shift toward HealthTech.

CEO Update | 27 June 2022

I was delighted to see the announcement from Moderna that it has chosen the UK to base its mRNA Innovation and Technology Centre and an additional mRNA manufacturing centre. Alongside other recent investments from the likes of Fujifilm and ThermoFisher, the UK is now superbly placed to ensure the next generation of therapeutics and vaccines are developed and manufactured for the globe right here within our world-class ecosystem.

Working with the UK’s rich health data

The UK has rich and diverse health data which provides exceptional opportunities for research and innovation. Despite this opportunity, the transformative potential of health data research is far from being realised in full. Only a fraction of NHS, biomedical and health-relevant data is accessible to inform research. It can take a very long time to apply for data access and have all the relevant approvals, checks and safeguards in place to do the analysis. And once data access is granted, data can of variable quality. Read this blog by Dr James Pickett, Hub Development Manager at HDR UK about creation of large, safe data sharing initiatives across the UK.

RBW Consulting wins Best Corporate Social Responsibility award

BIA member, RBW Consulting has just been named winner in the Best Corporate Social Responsibility category at the 2022 Best Business Awards. The award was in recognition of work tied to its IMPACT programme, which in the last year focused on a research initiative into the mental health impact of a rare disease diagnosis. The project has been recognised and endorsed by individuals and organisations from the rare disease community and was presented to over 150 people via webinar at launch.

Mayer Schreiber of Discovery Park on BIO International and how the Life Science community is transforming futures across the globe

BIO International and how the Life Science community is transforming futures across the globe

UK life sciences sector response to COVID-19 key for Moderna investment

Steve Bates OBE, Chief Executive of the BioIndustry Association and former member of the UK Vaccine Taskforce in 2020 said: “UK innovators look forward to welcoming the Moderna team into our collaborative and capable community.  The UK’s life science ecosystem’s innovation base, with Moderna’s new mRNA Innovation and Technology Centre and additional mRNA manufacturing centre stage, is now superbly placed to ensure the next generation of mRNA technologies, including next generation vaccines, are developed and manufactured for the globe from the UK." 

Coulter Partners D&I Interview Series: Industry perspectives with Tomoko Adachi

“… For us to drive innovation that addresses the diverse healthcare needs of our global society, we need a diverse team…” In the next interview in our Diversity, Equity & Inclusion Leadership series, we spoke to Tomoko Adachi, General Manager of Global HR and HR Business Partner for the Cardiac and Vascular Company at Terumo Corporation. Tomoko shares her insights in good D, E & I practice from her recent experience in medtech and compares this with what she has seen in the tech world, drawing on her 29-year tenure with Sony before Terumo.

George Freeman MP visits the site of eXmoor Pharma's future state-of-the-art facility in Patchway

eXmoor Pharma has outlined its ambitious global growth strategy for the next 18 months during a visit from the Minister for Science Research and Innovation, George Freeman MP. Unveiling its plans to be the flagship tenant-business at Bristol’s Patchway Trading estate, eXmoor CEO Angela Osborne met with George Freeman on Friday 10 June and discussed the importance of Government support in creating a new South West regional cell and gene therapy manufacturing cluster.